These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23473919)

  • 1. A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.
    Anderson E; Smith MA; Martin A; Ruddock M; Lamont J; Alloush H; Conway M; Mehta P; Smith JG; Salisbury V
    Leuk Res; 2013 Jun; 37(6):690-6. PubMed ID: 23473919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
    Anderson E; Mehta P; Heywood J; Rees B; Bone H; Robinson G; Reynolds D; Salisbury V; Mayer L
    Leuk Res; 2018 Nov; 74():121-129. PubMed ID: 30119908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients.
    Anderson E; Salisbury V
    Adv Biochem Eng Biotechnol; 2014; 145():189-214. PubMed ID: 25216956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation and verification of a bioluminescent biosensor for the quantitation of ara-CTP generation: a biomarker for cytosine arabinoside sensitivity in acute myeloid leukaemia.
    Anderson E; Conway M; Alloush H; O'Malley K; Smith MA; Martin A; Ruddock M; Reid C; Lamont J; Fitzgerald SP; Smith JG; Mehta P; Salisbury V
    Biosens Bioelectron; 2014 Feb; 52():345-53. PubMed ID: 24080214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V; Robertson LE; Keating MJ; Plunkett W
    Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
    Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
    Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.
    Freund A; Rössig C; Lanvers C; Gescher A; Hohenlöchter B; Jürgens H; Boos J
    Ann Oncol; 1999 Mar; 10(3):335-8. PubMed ID: 10355579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    Leuk Lymphoma; 1993; 10 Suppl():109-14. PubMed ID: 8481660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
    Ahlmann M; Lanvers C; Lümkemann K; Rössig C; Freund A; Baumann M; Boos J
    Leukemia; 2001 Jan; 15(1):69-73. PubMed ID: 11243402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
    Yamauchi T; Ueda T; Nakamura T
    Cancer Res; 1996 Apr; 56(8):1800-4. PubMed ID: 8620496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.